Single Dose of Bisphosphonate Preserves Gains in Bone Mass Following Cessation of Sclerostin Antibody in Brtl/+ Osteogenesis Imperfecta Model

Sclerostin antibody has demonstrated a bone-forming effect in pre-clinical models of osteogenesis imperfecta, where mutations in collagen or collagen-associated proteins often result in high bone fragility in pediatric patients. Cessation studies in osteoporotic patients have demonstrated that scler...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Bone
Prif Awduron: Perosky, Joseph E., Khoury, Basma M., Jenks, Terese N., Ward, Ferrous S., Cortright, Kai, Meyer, Bethany, Barton, David K., Sinder, Benjamin P., Marini, Joan C., Caird, Michelle S., Kozloff, Kenneth M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5077648/
https://ncbi.nlm.nih.gov/pubmed/27641475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2016.09.013
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg